news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

"this is a once-in-a-lifetime opportunity, a major good news, and a historic moment." yang ting, deputy director of the respiratory center of the china-japan friendship hospital, national center for respiratory medicine, expressed the above sentiment at the china-france medical day forum held during the china international fair for trade in services on september 13.

the news yang ting mentioned was that on the 13th, the national health commission, the ministry of finance and other departments announced that health services for patients with chronic obstructive pulmonary disease (copd) were included in the national basic public health service project. local primary medical and health institutions will gradually establish "health files" for confirmed copd patients in their jurisdictions, and provide free follow-up visits, routine examinations and other health services.

copd is the third most common chronic disease in china after hypertension and diabetes. the results of the china adult lung health study show that there are nearly 100 million copd patients in china. copd is also the third most lethal disease in china, with more than 1 million deaths from copd in china each year, an average of 2.5 deaths per minute.

over the years, well-known experts in the respiratory field, such as zhong nanshan and wang chen, have repeatedly called for copd to be included in the basic public health program. now, this expectation has finally been realized. on september 13, academician zhong nanshan also publicly stated that as a medical worker in the field of respiratory medicine, i am deeply excited. copd has been included in the national basic public health, the capacity of primary medical services has been enhanced, and high-quality medical resources have been further transferred to the grassroots level. ordinary people can enjoy more convenient, efficient and standardized medical services at their doorstep. i also call on all sectors to pay attention to copd, improve disease awareness, and provide standardized diagnosis and treatment.

"once it is included in the basic public health projects, medical staff at the grassroots level will pay more attention to it and will attach the same importance to copd as they do to hypertension and diabetes, so that common and frequently occurring diseases that are equally serious as hypertension and diabetes will receive the attention and intervention they deserve, so the significance is significant." wang chen, vice president of the chinese academy of engineering and president of the chinese academy of medical sciences, also publicly stated that the inclusion of copd in the basic public health projects is also very important for the prevention and treatment of respiratory infectious diseases. it can enable the grassroots medical system to always maintain an ability and state to deal with respiratory diseases, including copd and acute respiratory infectious diseases, so it is an effective means of "combining peace and epidemics."

pharmaceutical companies that focus on copd are also excited about the latest policy. as for multinational pharmaceutical companies, astrazeneca, glaxosmithkline, sanofi, and casey all have relevant drugs or pipelines. casey is an italian pharmaceutical company, and the respiratory field is one of its areas of expertise. deng haoqing, president and general manager of casey china, told the paper that the public awareness of copd in china is less than 10%, and only 12% of copd patients have undergone lung function tests. the latest policy will greatly help to increase public awareness and lung function testing rates, and promote early diagnosis and treatment of copd and standardized treatment at the grassroots level.

at present, the main treatment goal of copd is to alleviate symptoms and reduce the risk of acute exacerbations in the future, including preventing disease progression, preventing and treating acute exacerbations, and reducing mortality. chen rongchang, former chairman of the chinese medical association's respiratory diseases branch, head of the respiratory therapy group, and director of the shenzhen institute of respiratory diseases, said that global research on the treatment of copd has made new progress, and some innovative breakthroughs such as the emergence of biological targeted therapeutic drugs have brought new hope to patients, helping them control disease symptoms, reduce the risk of acute exacerbations, and improve their quality of life. it is believed that as my country's drug review reform continues to deepen, chinese patients will be able to access the latest international therapeutic drugs more quickly in the future and achieve copd treatment synchronized with the world.

globally, many copd drugs have made progress and are expected to benefit chinese patients. in july this year, sanofi announced that the european medicines agency (ema) has approved dupixent as an additional maintenance treatment for adult copd patients with elevated blood eosinophils and poorly controlled copd. at that time, sanofi china introduced that the drug had also submitted a marketing authorization application in china and was accepted by the center for drug evaluation (cde) of the national medical products administration.

deng haoqing introduced that casey has been continuously introducing innovative products and officially launched the "longteng plan" this year, continuing to increase investment in china, enriching the respiratory product portfolio, expanding the respiratory market coverage, and continuously providing more innovative treatment options for chinese copd patients to meet actual clinical needs and improve patients' quality of life.

as for domestic pharmaceutical companies, kangyuan pharmaceutical (600380) recently mentioned in its investor relations activity record that the company's products on the market are currently mainstream drugs for the treatment of chronic obstructive pulmonary disease. the company has also actively deployed new biological agents such as il-4r and tslp, and will continue to deepen its presence in the respiratory disease track. in may this year, hengrui medicine (600276) also announced that its subsidiary guangdong hengrui medicine co., ltd. received the "drug clinical trial approval notice" for shr-1905 injection approved by the national medical products administration, agreeing to conduct clinical trials for this product for chronic obstructive pulmonary disease.